RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Exploring determinants of psoriasis patients' treatment choices
A discrete-choice experiment study in the United States and Germany
Feldman, S. R., Poulos, C., Gilloteau, I., Mange, B., Boehm, K., Boeri, M., Naatz, M., & Augustin, M. (2022). Exploring determinants of psoriasis patients' treatment choices: A discrete-choice experiment study in the United States and Germany. Journal of Dermatological Treatment, 33(3), 1511-1520. https://doi.org/10.1080/09546634.2020.1839007, https://doi.org/10.1080/09546634.2020.1839007
BackgroundBiologic psoriasis treatments are differentiated by efficacy, side effects, and other attributes.ObjectiveDetermine attributes of biologic psoriasis treatments that drive patients' treatment choices.MethodsRespondents (USA: n = 300; Germany: n = 300) with moderate-to-severe psoriasis completed a discrete-choice-experiment survey, choosing between hypothetical treatments characterized by attributes with varying levels: chance of clear skin after 1 year, number of first-year treatments, first-year risks of mild-to-moderate injection site reaction (ISR) and serious infection, and years of proven efficacy/safety.ResultsU.S. respondents most valued clear skin (conditional relative importance, 1.88; p < .05). While other attributes were of generally equivalent importance, ISR risk outweighed serious-infection risk (1.06 vs. 0.70; p < .05). German respondents placed greatest importance on ISR risk (1.61; p < .05) and clear skin (1.49; p < .05).LimitationsRespondents evaluated hypothetical treatments and were recruited from web panels.ConclusionsClear skin and ISR risk are stronger drivers of treatment choice than injection frequency and infection risk.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.